Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC).
Atezolizumab plus bevacizumab has been shown to improve overall survival significantly and is the new standard of care for unresectable or metastatic HCC.
"This collaboration leverages Roche's deep experience in hepatocellular carcinoma and Surface's commitment to rationally and rapidly develop SRF388, a first-in-class antibody against IL-27, to provide a meaningful benefit to patients with liver cancer," said Surface Oncology chief medical officer Alison O'Neill.
Price Action: SURF shares are down 1.68% at $8.91 during the market session on the last check Friday.

Benzinga